Costunolide, a Sesquiterpene Lactone, Protects Against Platelet Activation and Thrombus Formation
Open Access
Abstract
Background/Objectives: Circulating platelets mediate physiological hemostasis and are implicated in pathological thrombosis, which can cause vascular occlusion, leading to heart attacks or strokes. Costunolide is a sesquiterpene lactone extracted from Saussurea lappa. Although this lactone has multiple biological effects, including anti-inflammatory and antioxidant effects, that help slow the progression of atherosclerosis, its influence on platelet activation remains unclear. In this study, we examined the potential antiplatelet and antithrombotic effects of costunolide. Methods: We used platelet aggregation, flow cytometry, and Western blot analysis to examine its in vitro antiplatelet effects. Results: Our results indicated that costunolide inhibited platelet aggregation induced by collagen, but not by thrombin or the thromboxane A2 analog U46619, suggesting that costunolide selectively inhibits collagen-induced platelet activation. Additionally, costunolide blocked collagen-mediated granule release, calcium mobilization, and glycoprotein IIb/IIIa (GPIIb/IIIa) activation. Costunolide also inhibited phospholipase Cγ2 (PLCγ2), pleckstrin (a downstream target of protein kinase C), Akt, and mitogen-activated protein kinase. Moreover, it prevented collagen/epinephrine-induced pulmonary thrombosis and increased the survival rate of mice. Furthermore, costunolide delayed thrombus formation in the mesenteric vessels while it did not significantly affect hemostasis, suggesting it exhibits antithrombotic activity without bleeding tendency. These findings indicate that costunolide can block PLCγ2-PKC, Akt, and MAPK signaling pathways and subsequent granule release, calcium mobilization, and GPIIb/IIIa activation, eventually impeding platelet activation, platelet aggregation, and thrombus formation. Conclusions: In conclusion, besides its multiple biological activities that are beneficial for slowing the progression of atherosclerosis, we also demonstrated the antiplatelet and antithrombotic activities of costunolide. These effects highlight the therapeutic potential of costunolide in the treatment of patients with cardiovascular disease, particularly stroke and heart attack.Keywords
Funding Information
- National Science and Technology Council (NSTC 114-2302-B-038-033-MY3)
- National Science and Technology Council (NSTC 109-2320-B-715-003-MY3)
- National Science and Technology Council (NSTC 111-2628-B-715-002-MY3)
- National Science and Technology Council (NSTC 114-2320-B-715-002-MY3)
- National Science and Technology Council (NSTC 109-2320-B-038-044-MY3)
- National Science and Technology Council (NSTC 111-2813-C-038-079-B)
- National Science and Technology Council (NSTC 112-2320-B-715-004)
- National Science and Technology Council (NSTC 113-2320-B-715-002-MY3)
- National Science and Technology Council (NSTC 114-2811-B-715-004)
- National Science and Technology Council (NSTC 110-2320-B-038-086)
- National Science and Technology Council (NSTC 113-2320-B-195-002)
- Mackay Memorial Hospital (MMH-114-11)
- Mackay Memorial Hospital (MMH-MM-114-11)
- Mackay Memorial Hospital (MMH-MM-115-17)
- Mackay Memorial Hospital (MMH-115-047)
- MacKay Medical University (MMU-RD-109-CF-G2-01)
- MacKay Medical University (MMU-RD-110-CF-G002-01)
- MacKay Medical University (MMU-RD-112-2A-P003)
This publication has 48 references indexed in Scilit:
- NLRP3 Inflammasome Inhibition by the Novel Bispecific Antibody InflamAb Attenuates Atherosclerosis in Apolipoprotein E–Deficient MiceJACC: Basic To Translational Science, 2025
- Platelets in Thrombosis and AtherosclerosisThe American Journal of Pathology, 2024
- Costunolide mitigates inflammation and promotes extracellualr matrix integrity of thoracic aortic dissection by inhibiting NF-κB signalingInternational Immunopharmacology, 2024
- Inhibition of TAK1/TAB2 complex formation by costunolide attenuates obesity cardiomyopathy via the NF-κB signaling pathwayPhytomedicine, 2022
- Costunolide covalently targets NACHT domain of NLRP3 to inhibit inflammasome activation and alleviate NLRP3-driven inflammatory diseasesActa Pharmaceutica Sinica B, 2022
- The multifaceted contribution of platelets in the emergence and aftermath of acute cardiovascular eventsAtherosclerosis, 2021
- Glycoprotein VI - novel target in antiplatelet medicationPharmacology & Therapeutics, 2021
- Costunolide inhibits osteosarcoma growth and metastasis via suppressing STAT3 signal pathwayBiomedicine & Pharmacotherapy, 2020
- TLR4 in AtherogenesisJACC, 2018
- Endothelial Cell-Specific NF-κB Inhibition Protects Mice from AtherosclerosisCell Metabolism, 2008